LENZ Therapeutics, Inc. Stock OTC Markets
Stocks
GRPH
US52635N1037
Biotechnology & Medical Research
OTC Markets Traded|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.800 USD | -78.44% |
|
-4.79% | +21.37% |
| Market Cap | 156M 137M 126M 116M 220M 15.05B 224M 1.51B 591M 7.36B 588M 575M 25.36B | P/E 2026 * |
-1.11x | P/E 2027 * | -1.46x |
|---|---|---|---|---|---|
| Enterprise Value | 156M 137M 126M 116M 220M 15.05B 224M 1.51B 591M 7.36B 588M 575M 25.36B | EV / Sales 2026 * |
8.37x | EV / Sales 2027 * | 2.48x |
| Free-Float |
97.35% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: LENZ Therapeutics, Inc.
| 1 day | -2.75% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -78.44% | -4.79% | - | - | 156M | |
| +3.13% | +13.95% | +64.21% | +94.35% | 57.82B | |
| +0.69% | -5.22% | +55.39% | +72.58% | 53.71B | |
| -2.44% | -8.73% | +3.20% | +421.45% | 23.8B | |
| +0.02% | -0.81% | -18.01% | -13.97% | 23.26B | |
| -0.56% | +10.26% | +44.03% | -3.86% | 20.7B | |
| -0.29% | -2.20% | +34.20% | -29.73% | 17.81B | |
| -4.55% | -8.65% | +194.32% | +349.58% | 16.9B | |
| -2.61% | +8.99% | +46.11% | +691.67% | 16.36B | |
| +0.58% | -1.89% | +25.02% | +191.92% | 13.96B | |
| Average | -0.89% | +1.68% | +49.83% | +197.11% | 27.15B | |
| Weighted average by Cap. | +0.11% | +1.51% | +50.15% | +156.97% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 18.7M 16.35M 15.08M 13.86M 26.27M 1.8B 26.71M 180M 70.64M 879M 70.22M 68.68M 3.03B | 63.18M 55.24M 50.96M 46.84M 88.75M 6.08B 90.27M 608M 239M 2.97B 237M 232M 10.24B |
| Net income | -142M -124M -114M -105M -199M -13.62B -202M -1.36B -535M -6.66B -532M -520M -22.95B | -111M -96.81M -89.31M -82.1M -156M -10.65B -158M -1.07B -418M -5.21B -416M -407M -17.95B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- LENZ Stock
- GRPH Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
